Clinical trial · Interventional
The Efficacy of Intravenous Iron for the Treatment of Anemia in Cancer Patients
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
* Multifactorial pathogenesis is involved in anemia of cancer patients and defining the causes of anemia is not always simple. * Currently, treatment options available for anemia in cancer patients include red blood cell (RBC) transfusion, erythropoietin stimulating agent (ESA), and iron supplementation, accompanying considerable pros and cons for each treatment. * Previous studies have demonstrated benefit when treating with IV iron in combination with ESA and, more recently, evidence is emerging to suggest a role for IV iron alone. * In this study, investigator will assess the efficacy of intravenous iron for the treatment of anemia in cancer patients.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Anemia | — | UNRESOLVED | — |
| Cancer | Malignant Neoplasm | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Ferinject® | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Subjects
- interventionNames
- Drug: Ferinject®
Primary outcomes (1)
- measure
- Number of participants with Hemoglobin response
- timeFrame
- visit 4th after Ferinject injection
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Subjects who diagnosed with solid cancer or lymphoma * Subjects who are under anti-cancer therapy at enrollment or has finished anti-cancer therapy within 2 months before enrollment * anticancer therapy: "chemotherapy", and/or "chemotherapy + radiotherapy", and/or "target agent" * Subjects whose Hb level is 8.0-10.5g/dL, or who experienced a drop of Hb by 2g/dL or more during anti-cancer treatment Exclusion Criteria: * Subjects who received iron (oral or iv), ESA, dialysis within 4 weeks before enrollment * Subjects with uncontrolled infection * Subjects with ongoing bleeding * Deteriorated organ function * poor performance state (ECOG 3-4) * Subjects whose disease involves bone marrow * Ferritin \> 800 ng/ml and Transferrin saturation(TSAT) ≥ 50%
References
Publications (1)
- DERIVEDJang JH, Kim Y, Park S, Kim K, Kim SJ, Kim WS, Jung CW, Lee J, Lee SH. Efficacy of intravenous iron treatment for chemotherapy-induced anemia: A prospective Phase II pilot clinical trial in South Korea. PLoS Med. 2020 Jun 8;17(6):e1003091. doi: 10.1371/journal.pmed.1003091. eCollection 2020 Jun. PMID 32511251